Literature DB >> 16785528

Analysis of TLR4 polymorphic variants: new insights into TLR4/MD-2/CD14 stoichiometry, structure, and signaling.

Prasad Rallabhandi1, Jessica Bell, Marina S Boukhvalova, Andrei Medvedev, Eva Lorenz, Moshe Arditi, Val G Hemming, Jorge C G Blanco, David M Segal, Stefanie N Vogel.   

Abstract

TLR4 is the signal-transducing receptor for structurally diverse microbial molecules such as bacterial LPS, respiratory syncytial virus fusion (F) protein, and chlamydial heat shock protein 60. Previous studies associated two polymorphic mutations in the extracellular domain of TLR4 (Asp(299)Gly and Thr(399)Ile) with decreased LPS responsiveness. To analyze the molecular basis for diminished responsiveness, site-specific mutations (singly or coexpressed) were introduced into untagged and epitope (Flag)-tagged wild-type (WT) TLR4 expression vectors to permit a direct comparison of WT and mutant signal transduction. Coexpression of WT TLR4, CD14, and MD-2 expression vectors in HEK293T cells was first optimized to achieve optimal LPS-induced NF-kappaB reporter gene expression. Surprisingly, transfection of cells with MD-2 at high input levels often used in the literature suppressed LPS-induced signaling, whereas supraoptimal CD14 levels did not. Under conditions where WT and polymorphic variants were comparably expressed, significant differences in NF-kappaB activation were observed in response to LPS and two structurally unrelated TLR4 agonists, chlamydial heat shock protein 60 and RSV F protein, with the double, cosegregating mutant TLR4 exhibiting the greatest deficiency. Overexpression of Flag-tagged WT and mutant vectors at input levels resulting in agonist-independent signaling led to equivalent NF-kappaB signaling, suggesting that these mutations in TLR4 affect appropriate interaction with agonist or coreceptor. These data provide new insights into the importance of stoichiometry among the components of the TLR4/MD-2/CD14 complex. A structural model that accounts for the diminished responsiveness of mutant TLR4 polymorphisms to structurally unrelated TLR4 agonists is proposed.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16785528     DOI: 10.4049/jimmunol.177.1.322

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  93 in total

Review 1.  TLR4 polymorphisms and disease susceptibility.

Authors:  Mamoona Noreen; Muhammad Ali A Shah; Sheeba Murad Mall; Shazia Choudhary; Tahir Hussain; Iltaf Ahmed; Syed Fazal Jalil; Muhammad Imran Raza
Journal:  Inflamm Res       Date:  2012-01-26       Impact factor: 4.575

Review 2.  IBD-what role do Proteobacteria play?

Authors:  Indrani Mukhopadhya; Richard Hansen; Emad M El-Omar; Georgina L Hold
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2012-02-21       Impact factor: 46.802

3.  Association of TLR4 polymorphism with cytokine expression level and pulmonary lesion score in pigs.

Authors:  X Q Yang; E Murani; S Ponsuksili; K Wimmers
Journal:  Mol Biol Rep       Date:  2012-02-04       Impact factor: 2.316

4.  A toll-like receptor 9 (rs352140) variant is associated with placental inflammation in newborn infants.

Authors:  Vijender Karody; Shawn Reese; Navin Kumar; Jennifer Liedel; Jason Jarzembowski; Venkatesh Sampath
Journal:  J Matern Fetal Neonatal Med       Date:  2015-09-15

5.  Toll-like receptor 4 polymorphisms in dengue virus-infected children.

Authors:  Kis Djamiatun; Bart Ferwerda; Mihai G Netea; André J A M van der Ven; Wil M V Dolmans; Sultana M H Faradz
Journal:  Am J Trop Med Hyg       Date:  2011-08       Impact factor: 2.345

6.  Vibrio cholerae flagellins induce Toll-like receptor 5-mediated interleukin-8 production through mitogen-activated protein kinase and NF-kappaB activation.

Authors:  Lisa M Harrison; Prasad Rallabhandi; Jane Michalski; Xin Zhou; Susan R Steyert; Stefanie N Vogel; James B Kaper
Journal:  Infect Immun       Date:  2008-09-22       Impact factor: 3.441

7.  Radioiodination of an endotoxin·MD-2 complex generates a novel sensitive, high-affinity ligand for TLR4.

Authors:  Athmane Teghanemt; Jerrold P Weiss; Theresa L Gioannini
Journal:  Innate Immun       Date:  2013-02-25       Impact factor: 2.680

8.  Toll-like receptor 4 Asp299Gly and Thr399Ile polymorphisms in gastric cancer of intestinal and diffuse histotypes.

Authors:  D Santini; S Angeletti; A Ruzzo; G Dicuonzo; S Galluzzo; B Vincenzi; A Calvieri; F Pizzagalli; N Graziano; E Ferraro; G Lorino; A Altomare; M Magnani; F Graziano; G Tonini
Journal:  Clin Exp Immunol       Date:  2008-09-29       Impact factor: 4.330

9.  Donor Toll-like receptor 4 contributes to ischemia and reperfusion injury following human kidney transplantation.

Authors:  Bernd Krüger; Stefanie Krick; Navdeep Dhillon; Susan M Lerner; Scott Ames; Jonathan S Bromberg; Marvin Lin; Liron Walsh; John Vella; Michael Fischereder; Bernhard K Krämer; Robert B Colvin; Peter S Heeger; Barbara T Murphy; Bernd Schröppel
Journal:  Proc Natl Acad Sci U S A       Date:  2009-02-13       Impact factor: 11.205

10.  Vibrio cholerae proteome-wide screen for immunostimulatory proteins identifies phosphatidylserine decarboxylase as a novel Toll-like receptor 4 agonist.

Authors:  Ann Thanawastien; Wagner R Montor; Joshua Labaer; John J Mekalanos; Sang Sun Yoon
Journal:  PLoS Pathog       Date:  2009-08-21       Impact factor: 6.823

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.